517.65↑-6.20 (-1.18%)
12:00 AM,4th Oct 2023510.20↑-7.95 (-1.53%)
09:09 AM,5th Oct 2023BSE : 531633
NSE : LINCOLN
Sector : Health care
ISIN Code : INE405C01035
Last Updated: Oct 05 2023 | 09:09 AM IST
Market Cap (₹ Cr) | 1036 |
Turnover (₹ Cr) | 0.28 |
Volume (Shares) | 53525 |
Face Value | 10 |
52-WK High | 543.25 |
52-WK High Date | 11 Sep 2023 |
52-WK Low | 285.00 |
52-WK Low Date | 10 Oct 2022 |
All Time High | 543.25 |
All Time High Date | 11 Sep 2023 |
All Time Low | 85.05 |
All Time Low Date | 19 Mar 2020 |
Lincoln Pharmaceuticals Limited promoted by Mahendra G Patel Rajnikant G Patel and Hasmukhbhai I Patel as a Partnership Firm in Jan 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The company was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda Gujarat for manufacturing tablets capsules liquid and powder syrups and ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district) Gujarat to manufacture small volume parenterals like dry powder injectables liquid vial liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.'96 to part-finance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 2021-22 Lincoln Parenteral Limited (Transferor Company) an erstwhile subsidiary merged with Lincoln Pharmaceuticals Limited (the Transferee Company) through the Scheme of Amalgamation and consequent to this the Transferor Company ceases to be the subsidiary of the Company. The Company acquired a plant in Mehsana Gujarat to launch Cephalosporin products in 2022.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 1036 |
EPS - TTM (₹) [S] | 38.39 |
P/E Ratio (X) [S] | 2.06 |
Face Value (₹) | 10 |
Latest Dividend (%) | 15.00 |
Latest Dividend Date | 15 Sep 2023 |
Dividend Yield (%) | 0.29 |
Book Value Share (₹) [S] | 250.86 |
P/B Ratio (₹) [S] | 2.06 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF | 0.01 | 102 | 0.07 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 513.35 528.80 |
Week Low/High | 499.85 534.00 |
Month Low/High | 491.80 543.00 |
Year Low/High | 285.00 543.00 |
All time Low/High | 8.05 543.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 2.21% | 2.21% | -0.79 | -1.42% |
1 Month | -0.03% | -0.06% | -0.05 | -0.47% |
3 Month | 27.45% | 27.28% | 0.18 | 0.24% |
6 Month | 47.02% | 47.04% | 10.98 | 11.71% |
1 Year | 78.01% | 78.13% | 12.97 | 12.51% |
3 Year | 103.24% | 103.12% | 69.52 | 70.24% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
10-08-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 132733 | 480.98 |
10-08-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 132733 | 480.98 |
07-10-2021 | SWETSAM STOCK HOLDING PRIVATE LIMITED | NSE | BUY | 146927 | 395.19 |
07-10-2021 | SWETSAM STOCK HOLDING PRIVATE LIMITED | NSE | SELL | 93927 | 396.19 |
23-07-2021 | MBL & CO. LIMITED | NSE | BUY | 108405 | 368.08 |
23-07-2021 | MBL & CO. LIMITED | NSE | SELL | 103857 | 369.48 |
13-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 137276 | 370.10 |
13-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 137276 | 370.33 |
29-06-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 179634 | 340.02 |
29-06-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 179634 | 339.84 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 48.67 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 1.74 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.00 |
Indian Public | 37.32 |
Others Non Institutional Investors | 12.26 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman (Non-Executive) : Kishorbhai M Shah
Managing Director : Mahendra G Patel
Whole-time Director : Hasmukhbhai I Patel
Independent Director : Pirabhai R Suthar
Whole-time Director : Munjal Mahendrabhai Patel
Whole-time Director : Aashish R Patel
Independent Director : Meha Patel
Independent Director : Saurin J Parikh
Director : Rajnikant G Patel
Whole-time Director : Anand Arvindbhai Patel
Company Sec. & Compli. Officer : Trusha Shah
Registered Office: Lincoln House B/H Satyam Compe, Science City Road Sola,Ahmedabad,Gujarat-380060 Ph: 91-079-67778000
Email:info@lincolnpharma.com